Novo Nordisk and Omeros announce asset purchase and license
Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk’s Rare Disease…
What’s likely to move the market in the next trading session
Stocks @ Night is a daily newsletter delivered after hours, giving you a first look at tomorrow and…
Eli Lilly plans $6.5 billion Texas manufacturing plant for obesity pill
A rendering of Eli Lilly’s manufacturing facility in Houston, Texas. Courtesy: Eli Lilly Eli Lilly on Tuesday said…
Our 3 best and worst stocks over the past month as Fed rate cut speculation swirled
The stock market hit record high after record high over the past month as Wall Street anticipated a…
Eli Lilly to build $5 billion Virginia manufacturing facility
Eli Lilly Biotechnology Center is shown in San Diego, California, March 1, 2023. Mike Blake | Reuters Eli…
CPI report health care inflation rises
Jose Luis Pelaez Inc | Digitalvision | Getty Images Health-care inflation is fueling higher coverage costs, setting the…
What’s likely to move the market in the next trading session
Stocks @ Night is a daily newsletter delivered after hours, giving you a first look at tomorrow and…
Eli Lilly weight loss pill orforglipron clears trial, paving way for approval
Eli Lilly Biotechnology Center is shown in San Diego, California, U.S. March 1, 2023. Mike Blake | Reuters…
FDA approves Signos glucose monitoring for weight loss
Woman with Signos wearable and app Source: Signos The Food and Drug Administration on Wednesday approved the first-ever…
Meta shares fall on AI restructuring report, while Lilly shrugs off Novo’s Ozempic price move
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just…